Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Andrea DeCensi(Memorial Sloan Kettering Cancer Center), Bernardo Bonanni(European Institute of Oncology), Antonio Ponti(Piedmont Reference Center for Epidemiology and Cancer Prevention), Davide Serrano(European Institute of Oncology), Matteo Lazzeroni(European Institute of Oncology), Franca Avino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marcella Gulisano(Azienda Industriali Municipali di Vicenza (Italy)), Tania Buttiron Webber(Ente Ospedaliero Ospedali Galliera), Harriet Johansson(European Institute of Oncology), Fabio Falcini(Centro di Riferimento Oncologico), Maria Grazia Pacquola(Ospedale Sant Antonio), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Irene Maria Briata(Ente Ospedaliero Ospedali Galliera), Aliana Guerrieri‐Gonzaga(European Institute of Oncology), Luca Boni(Ospedale Policlinico San Martino), Anna Cariello(Azienda Unità Sanitaria Locale Della Romagna), Maria Digennaro, Silvia Caviglia(Ente Ospedaliero Ospedali Galliera), Graziella Pinotti(Medica (Italy)), Matteo Puntoni(University of Parma)
Cited by 23
Related Papers
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer
|Nature Medicine|2019|1.4k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k